<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR201.html">Part 201
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 201.316  Drugs with thyroid hormone activity for human use;
                            </h3>
                            <p class="depth1"><em>(a)</em> Drugs with thyroid hormone activity have been promoted for, and continue to be dispensed and prescribed for, use in the treatment of obesity, although their safety and effectiveness for that use have never been established.</p><p class="depth1"><em>(b)</em> Drugs for human use with thyroid hormone activity are misbranded within the meaning of section 502 of the Federal Food, Drug, and Cosmetic Act unless their labeling bears the following boxed warning at the beginning of the ``Warnings'' section:</p><p class="depth2">------------------------------------------------------------------</p><p class="depth2">Drugs with thyroid hormone activity, alone or together</p><p class="depth2">with other therapeutic agents, have been used for the</p><p class="depth2">treatment of obesity. In euthyroid patients, doses within</p><p class="depth2">the range of daily hormonal requirements are ineffective for</p><p class="depth2">weight reduction. Larger doses may produce serious or even</p><p class="depth2">life-threatening manifestations of toxicity, particularly</p><p class="depth2">when given in association with sympatho mimetic amines such</p><p class="depth2">as those used for their anorectic effects.</p><p class="depth2">------------------------------------------------------------------
[43 FR 22009, May 23, 1978]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
